
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF584 (zinc finger protein 584) encodes a predicted zinc finger transcription factor that may bind specific cis-regulatory regions associated with RNA polymerase II-dependent transcription. Through sequence-specific DNA binding, ZNF584 is predicted to participate in regulation of gene expression in the nucleus. The available annotation does not establish specific target genes, cellular pathways, or physiological functions, and its molecular mechanisms remain incompletely characterized.
JIMT-1 is a human breast cancer cell line established from the pleural effusion of a 62-year-old female patient with grade 3 invasive ductal breast carcinoma (T2N1M0) after postoperative radiation therapy. The cells carry amplification of the HER2 oncogene and have been reported to be insensitive to HER2-targeted therapies, including trastuzumab. JIMT-1 is widely used as a model for studying HER2-positive breast cancer biology, mechanisms of therapeutic resistance, and evaluation of novel anti-HER2 treatments.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_173548
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?